WWM
NBIX icon

Whalen Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Whalen Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$526K Sell
3,706
-2,457
-40% -$395K 0.22% 111
2026
Q2 		$1.04M Sell
6,163
-299
-5% -$44.4K 0.47% 64
2026
Q1 		$851K Buy
6,462
+1,337
+26% +$177K 0.46% 57
2025
Q4 		$727K Buy
5,125
+663
+15% +$96.1K 0.39% 68
2025
Q3 		$626K Buy
4,462
+833
+23% +$113K 0.37% 65
2025
Q2 		$456K Buy
3,629
+235
+7% +$26.9K 0.29% 103
2025
Q1 		$375K Buy
3,394
+1,461
+76% +$185K 0.25% 92
2024
Q4 		$264K Buy
+1,933
New +$239K 0.18% 107

Other funds holding NBIX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PCS
Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

Whalen Wealth Management's NBIX Position: Q3 2026 in Review

Whalen Wealth Management reduced its Neurocrine Biosciences (NBIX) stake by 40% in Q3 2026, selling an estimated $395K and leaving 3,706 shares worth $526K. The position accounts for 0.22% of the portfolio, ranked #111.

Whalen Wealth Management first reported a position in NBIX in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.04M in Q2 2026. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Whalen Wealth Management held 3,706 shares of Neurocrine Biosciences worth $526K as of Q3 2026.
  • Whalen Wealth Management sold 2,457 Neurocrine Biosciences shares in Q3 2026, an estimated $395K.
  • Neurocrine Biosciences made up 0.22% of Whalen Wealth Management's portfolio in Q3 2026, its #111 holding.
  • Whalen Wealth Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 8 quarters since.
  • Whalen Wealth Management's Neurocrine Biosciences position peaked at $1.04M in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Whalen Wealth Management's 13F filing for Q3 2026, filed 8 Oct 2026.